Devonian Health Group's Progress Towards NYSE American Listing Amidst Strategic Expansion

Devonian Health Group Updates NYSE American Listing Plans

Devonian Health Group Inc. (TSXV: GSD, OTCQB: DVHGF) made headlines recently with an update on its anticipated listing on the NYSE American. This announcement reflects Devonian's ongoing efforts in the pursuit of its initial public offering (IPO) in the United States. As of October 2026, the company continues to work diligently with its financial partner, ThinkEquity, to navigate the various steps necessary for the successful completion of this initiative.

In previous communications, notably on July 27, August 18, and September 11 of 2026, Devonian outlined its strategic objectives and the timeline for the upcoming listing. The company's commitment remains unwavering, as it aims to offer its common shares and warrants on the NYSE American under the trading symbols "DHGR" and "DHGR WS." Both symbols are indicative of the company's ambitious plans to tap into new investment opportunities.

Despite the optimistic outlook, it is crucial to note that the timing for trading commencement and the closing date for the Offering remain uncertain at this moment. The success of the IPO and NYSE listing depends on market conditions and the receipt of regulatory approvals, including those from the NYSE American LLC and the TSX Venture Exchange (TSXV). Thus, while the preparations are in progress, there is no guarantee of completion or the terms under which such events may unfold.

Devonian Health Group, founded in 2015 and based in Quebec, is a clinical-stage pharmaceutical company focusing on innovative therapeutic solutions for autoimmune fibroinflammatory diseases. From atopic dermatitis to ulcerative colitis, Devonian targets unmet medical needs with its state-of-the-art facilities and dedicated research initiatives. Currently, the company trades publicly on the TSXV and is accessible on the OTCQB Venture Market.

The journey toward an NYSE listing positions Devonian at the forefront of public interest, as investors look toward companies making strides in healthcare innovation. Devonian intends to keep stakeholders informed with press releases detailing any changes or updates regarding their trading timeline and listing status.

"We understand the importance of transparency with our investors and the market," said a representative from Devonian Health Group. "We are fully committed to fulfilling our objectives and look forward to sharing our progress as we navigate this crucial phase."

One aspect that highlights the significance of this move is that the Offering does not constitute a solicitation to sell or buy securities, particularly in jurisdictions where such transactions would violate existing laws. This regulatory caution is vital as Devonian ensures compliance with international standards while pursuing its growth.

The preparation for the NYSE American listing reflects Devonian’s ambition and strategic vision for the future. The company's fundamental belief in the potential of its pipeline and the importance of attracting increased institutional investment are driving forces behind this initiative.

As the landscape of healthcare innovation continues to evolve, investors will be watching closely as Devonian Health Group progresses through the final steps toward its anticipated listing. With its innovative approach to treating significant medical challenges, the company is poised to emerge as a leading player in pharmaceutical advancements. Stakeholders are encouraged to stay tuned for further information that will clarify the timeline and specifics of the Offering as they unfold.

For more information about Devonian Health Group and its ongoing projects, you can visit their official website here.